Nrx Pharmaceuticals, INC

NRx Pharmaceuticals' subsidiary, NRX Defense Systems, has been selected by DARPA for negotiation of a potential award for a clinical trial combining D-cycloserine with Transcranial Magnetic Stimulation.

NRx Pharmaceuticals has successfully closed an underwritten public offering of common stock, raising approximately $22.3 million in gross proceeds.

NRx Pharmaceuticals has announced its intention to conduct an underwritten public offering of its common stock to support working capital and general corporate growth.

NRx Pharmaceuticals' stockholders approved an amendment to its Omnibus Incentive Plan, significantly increasing the annual share reserve for equity awards.

NRx Pharmaceuticals announced a clear path to full New Drug Application approval for NRX-100, expanding its target indication and leveraging Real World Data following a Type C FDA meeting.

NRx Pharmaceuticals, Inc. filed a prospectus supplement for an At-The-Market offering of up to $20 million in common stock.

NRx Pharmaceuticals reported a significant increase in net loss for Q3 2025, while advancing multiple drug candidates and expanding its clinical services network.

NRx Pharmaceuticals reported a significantly wider net loss in Q2 2025 and raised substantial doubt about its ability to continue as a going concern, despite advancing key drug candidates and clinic acquisitions.

NRx Pharmaceuticals details its Q1 2025 financial results and operational progress, highlighting upcoming NDA submissions and the strategic expansion of its HOPE Therapeutics subsidiary.

NRx Pharmaceuticals' Q3 2024 report highlights progress in drug development, strategic financing, and a settlement, while acknowledging ongoing financial challenges.

NRx Pharmaceuticals announced its Q2 2024 financial results, highlighting a net loss of $14.4 million for the first six months of 2024, and secured $16.3 million in debt financing to support drug development.

NRx Pharmaceuticals reported its Q1 2024 financial results, showcasing advancements in clinical trials, strategic partnerships, and the development of novel therapeutics for central nervous system disorders.

NRx Pharmaceuticals reports significant progress in its neuroplasticity drug pipeline and the expansion of its interventional psychiatry subsidiary, HOPE Therapeutics, despite facing substantial financial losses and a going concern warning.

NRx Pharmaceuticals files an amendment to its 2024 annual report on Form 10-K to update information regarding directors, executive compensation, security ownership, related transactions, and accounting fees.

NRx Pharmaceuticals details its financial results for fiscal year 2024, emphasizing advancements in its drug pipeline and strategic shift towards revenue generation through HOPE Therapeutics.

NRx Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include information required by Part III, Items 10-14, and Part IV, Item 15, of the original filing.

NRx Pharmaceuticals' 10-K filing details a year of significant growth, strategic partnerships, and financial restructuring, positioning the company for future expansion.

NRX Pharmaceuticals' Chairman and Chief Scientist, Jonathan C. Javitt, was granted 125,000 stock options with an exercise price of $1.7297.

NRX Pharmaceuticals Director Dennis McBride was granted 25,000 stock options with an exercise price of $1.7297, vesting on April 9, 2026.

NRX Pharmaceuticals Director Chaim Hurvitz was granted 25,000 stock options with an exercise price of $1.7297, vesting in April 2026.

NRX Pharmaceuticals Director Patrick Flynn was granted 50,000 stock options with an exercise price of $1.7297, vesting in April 2026.

Michael Abrams, CFO of NRX Pharmaceuticals, reports the acquisition of stock options.

Jonathan Javitt, a director and officer of NRX Pharmaceuticals, purchased 40,000 shares of common stock at $1.17 per share on December 17, 2024.

NRx Pharmaceuticals, Inc. filed a supplement to its definitive proxy statement to correct proposal numbering for its upcoming March 23, 2026 annual meeting.

NRx Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, an equity incentive plan amendment, auditor ratification, and executive compensation.

NRx Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on October 8, 2024, to vote on key proposals including director elections, share issuance approval, a potential reverse stock split, and auditor ratification.

NRx Pharmaceuticals amends its proxy statement to include information about retaining Alliance Advisors LLC for proxy solicitation at a cost of approximately $50,000 plus expenses.

NRx Pharmaceuticals plans to distribute 49% of HOPE Therapeutics stock and a royalty right of 1% of Ketamine sales to existing NRXP shareholders and applicable warrant holders.

NRx Pharmaceuticals initiates a strategy to combat short selling, including a potential reverse stock split, name change, and engagement with former SEC enforcement leaders.

NRx Pharmaceuticals has filed a registration statement for the resale of 3.3 million shares of common stock by selling stockholders, stemming from the conversion of debt and exercise of warrants.

Anson Funds Management LP and affiliated entities have reported beneficial ownership of 4.9% of NRX Pharmaceuticals, Inc. common stock, including shares underlying warrants.

The B Group, Inc., B Group Capital LLC, and Branden B. Muhl have jointly disclosed a 12.62% beneficial ownership stake in NRx Pharmaceuticals, Inc.

Anson Funds Management LP and related entities have disclosed a 9.3% beneficial ownership stake in NRX Pharmaceuticals, Inc. common stock.

Anson Funds Management LP and its affiliates have disclosed a 7% passive beneficial ownership stake in NRX Pharmaceuticals, Inc., totaling 1,179,061 shares of common stock.